---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007951"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:22:48.414633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027

## Summary
- Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
- Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.
- IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.
- Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.
- Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer.

## SEC filing metadata
- accession: 0001558370-24-007951
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/0001558370-24-007951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/vygr-20240513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007951
- JSON: https://secwatch.observer/filing/0001558370-24-007951.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007951.txt

## Key facts
- Earnings Releases
  Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.
  - Period: first quarter 2024
  - Revenue: $19.5 million
  - Net income: $11.3 million
  - Result: reported results
  source text: INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. ​ First Quarter 2024 Financial Results ​ ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/0001558370-24-007951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.